$98.80
▼ -0.4% Today
as of Jul 22, 16:54 ET
Last 30 days
Recent Press Releases & News
Mizuho Raises Price Target on Spyre Therapeutics to $120 From $84, Keeps Outperform Rating
Spyre Therapeutics Insider Sold Shares Worth $1,315,346, According to a Recent SEC Filing
Spyre Therapeutics Announces Grants of Inducement Awards
Overview
52-week range
$14
$79
100% of range
Avg surprise (last 3)
+7.8%
Avg reaction (last 2)
+2.0%
100% positive
Latest IV / EM
77%
EM ±17.5% · $100 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-0.74 | $-0.66 | -12.1% | 0.0% | +2.7% | earnings |
| Tue Aug 5, 2025 | Jun/2025 | $-0.49 | $-0.73 | +32.9% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.74 | $-0.76 | +2.6% | — | +1.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $1.06 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.59 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.72 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.86 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $40.14 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | -$0.71 | -$0.49 | -44.9% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-46M | — | $-57M | $-42M | $-54M | — | $-55M | $-44M |
| Net income | $-69M | — | $-11M | $-37M | $-45M | — | $-69M | $-39M |
| EPS (diluted) | $-0.74 | — | — | — | — | — | $1.06 | $0.59 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $97M | $86M | $65M | $82M | $48M | $89M | $72M | $45M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $764M | $778M | $505M | $539M | $570M | $608M | $421M | $436M |
| Total assets | $764M | $778M | $505M | $539M | $570M | $608M | $421M | $436M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $93M | $63M | $50M | $83M | $87M | $91M | $94M | $62M |
| Total equity | $671M | $715M | $455M | $456M | $483M | $518M | $327M | $374M |